Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicare coverage of self-injectable products

Executive Summary

"South Carolina has the national distinction of being the only state in the U.S. where the Part B Carrier does not cover interferon for any indication...[or] the pre-operative use of epoetin alpha," Greenville, S.C. oncologist Mark O'Rourke told a recent HCFA "town hall" meeting. "The Pink Sheet" incorrectly listed products that O'Rourke considers to be "most-effectively administered by subcutaneous injection," including Amgen's Neupogen, Immunex' Leukine and Ortho's Procrit, as products not covered by the Medicare carrier (1"The Pink Sheet" July 31, p. 10)

You may also be interested in...

HCFA To Review Medicare Carrier Discretion On Self-Administered Drugs

HCFA is planning to review the amount of discretion that should be allowed to Medicare carriers on the coverage decisions for self-administerable drugs that were available through Medicare before 1997.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts